- Home
- AGIO vs JAMF Comparison
AGIO vs JAMF Comparison
Compare AGIO & JAMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- JAMF
- Stock Information
- Founded
- AGIO 2007
- JAMF 2002
- Country
- AGIO United States
- JAMF United States
- Employees
- AGIO N/A
- JAMF N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- JAMF Computer Software: Prepackaged Software
- Sector
- AGIO Health Care
- JAMF Technology
- Exchange
- AGIO Nasdaq
- JAMF Nasdaq
- Market Cap
- AGIO 1.4B
- JAMF 1.4B
- IPO Year
- AGIO 2013
- JAMF 2020
- Fundamental
- Price
- AGIO $39.23
- JAMF $8.14
- Analyst Decision
- AGIO Buy
- JAMF Buy
- Analyst Count
- AGIO 6
- JAMF 8
- Target Price
- AGIO $58.60
- JAMF $19.63
- AVG Volume (30 Days)
- AGIO 615.0K
- JAMF 1.2M
- Earning Date
- AGIO 07-31-2025
- JAMF 08-06-2025
- Dividend Yield
- AGIO N/A
- JAMF N/A
- EPS Growth
- AGIO N/A
- JAMF N/A
- EPS
- AGIO 11.45
- JAMF N/A
- Revenue
- AGIO $37,035,000.00
- JAMF $642,897,000.00
- Revenue This Year
- AGIO $22.30
- JAMF $12.65
- Revenue Next Year
- AGIO $219.19
- JAMF $9.06
- P/E Ratio
- AGIO $3.39
- JAMF N/A
- Revenue Growth
- AGIO 25.96
- JAMF 10.75
- 52 Week Low
- AGIO $23.42
- JAMF $8.01
- 52 Week High
- AGIO $62.58
- JAMF $19.05
- Technical
- Relative Strength Index (RSI)
- AGIO 70.51
- JAMF 24.81
- Support Level
- AGIO $34.60
- JAMF $8.70
- Resistance Level
- AGIO $40.06
- JAMF $9.26
- Average True Range (ATR)
- AGIO 1.45
- JAMF 0.30
- MACD
- AGIO 0.43
- JAMF -0.07
- Stochastic Oscillator
- AGIO 88.98
- JAMF 3.61
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About JAMF Jamf Holding Corp.
Jamf Holding Corp is the standard in Apple Enterprise Management, and its cloud software platform is the vertically focused Apple infrastructure and security platform. The company helps organizations, including businesses, hospitals, schools, and government agencies, connect, manage, and protect Apple products, apps, and corporate resources in the cloud without ever having to touch the devices. It sells its Software-as-a-Service, or SaaS, solutions via a subscription model, through a direct sales force, online, and indirectly via its channel partners, including Apple. The company operates in The Americas; Europe, the Middle East, India, and Africa; and Asia Pacific.